Nicholas M. Durham

4.4k total citations
30 papers, 1.5k citations indexed

About

Nicholas M. Durham is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Nicholas M. Durham has authored 30 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 16 papers in Immunology and 7 papers in Genetics. Recurrent topics in Nicholas M. Durham's work include CAR-T cell therapy research (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Immunotherapy and Immune Responses (10 papers). Nicholas M. Durham is often cited by papers focused on CAR-T cell therapy research (15 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Immunotherapy and Immune Responses (10 papers). Nicholas M. Durham collaborates with scholars based in United States, United Kingdom and Netherlands. Nicholas M. Durham's co-authors include Charles G. Drake, Tullia C. Bruno, Derese Getnet, Christopher J. Nirschl, Christopher M. Jackson, Ching Ching Leow, Robert E. Hollingsworth, Joseph F. Grosso, Jonathan Rios‐Doria and Raymond Rothstein and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Nicholas M. Durham

26 papers receiving 1.5k citations

Peers

Countries citing papers authored by Nicholas M. Durham

Since Specialization

Citations

This map shows the geographic impact of Nicholas M. Durham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas M. Durham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas M. Durham more than expected).

Fields of papers citing papers by Nicholas M. Durham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas M. Durham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas M. Durham. The network helps show where Nicholas M. Durham may publish in the future.

Co-authorship network of co-authors of Nicholas M. Durham

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas M. Durham. A scholar is included among the top collaborators of Nicholas M. Durham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas M. Durham. Nicholas M. Durham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CLDN18/CLDN18.2 IHC assay comparison (SP455, 43-14A, EPR19202) and co-prevalence expression with other biomarkers in gastric carcinoma. 2024 ·Journal of Clinical Oncology ·(unknown), Sophie E. Willis, (unknown), (unknown), (unknown), (unknown), Chris G. Richardson, Andrew G. Chambers, Yeoun Jin Kim, Tsu‐Shuen Tsao, Mark D. Robida, Jan Maciej Zaucha, Deborah L. Berry, Gemma N. Jones, Allison Barrett, Nicholas M. Durham, Marlon C. Rebelatto, Maria A.S. Broggi, Kenneth S. Thress, Nicolás A. Giraldo	1
2	Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors 2024 ·Journal for ImmunoTherapy of Cancer ·Diwakar Davar, Benedito A. Carneiro, Grace K. Dy, Siddharth Sheth, Mitesh J. Borad, Kevin J. Harrington, Sandip Pravin Patel, Evanthia Galanis, Adel Samson, (unknown), Yuyan Chen, (unknown), (unknown), J.L. Burton, Eric Tu, Nicholas M. Durham, Kevin Laubscher, Fernanda I. Arnaldez, Dmitriy Zamarin	9
3	IL-12 encoding oNDV synergizes with CAR-T cells in orthotopic models of non-small cell lung cancer 2024 ·PubMed ·Amanda Rosewell Shaw, Daisuke Morita, Caroline E. Porter, Eric Tu, Greyson Biegert, Sonia Agrawal, Nicholas M. Durham, Malcolm K. Brenner, Masataka Suzuki	0
4	Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma 2022 ·Clinical Cancer Research ·Charu Aggarwal, Nabil F. Saba, Alain P. Algazi, Ammar Sukari, Tanguy Y. Seiwert, Missak Haigentz, Mercedes Porosnicu, Marcelo Bonomi, Jean Boyer, Mark T. Esser, Lily Cheng, Sonia Agrawal, Emily C. Jennings, Nicholas M. Durham, (unknown), (unknown), (unknown), (unknown), (unknown), Rakesh Kumar	26
5	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T _H 1 response with a diverse TCR repertoire 2021 ·Science Translational Medicine ·Phillip A. Swanson, Marcelino Padilla, (unknown), Kelly McGlinchey, Paul Fields, Sagida Bibi, Saul N. Faust, Adrian B. McDermott, Teresa Lambe, Andrew J. Pollard, Nicholas M. Durham, Elizabeth J. Kelly, (unknown)	59
6	Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity 2021 ·Molecular Cancer Therapeutics ·James A. Harper, Shannon Burke, Jon Travers, Nicola Rath, (unknown), (unknown), (unknown), Rebecca Leyland, Kathy Mulgrew, Kelly McGlinchey, Lee R. Brown, Simon J. Dovedi, Jens‐Oliver Koopmann, Nicholas M. Durham, Xing Cheng, Hong Jin, Jim Eyles, Robert W. Wilkinson, Danielle Carroll	10
7	A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade 2020 ·Molecular Cancer Research ·(unknown), Han Si, Todd Creasy, Koustubh Ranade, Brandon W. Higgs, Katie Streicher, Nicholas M. Durham	10
8	Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors 2020 ·Clinical Cancer Research ·Ani Sarkis Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael S. Gordon, Philip R. Mallinder, Nairouz Elgeioushi, Ignacio Ferreira González, Nathan Standifer, Jennifer Cann, Nicholas M. Durham, (unknown), Rakesh Kumar, Crystal S. Denlinger	40
9	916MO Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC) 2020 ·Annals of Oncology ·Charu Aggarwal, Nabil F. Saba, Alain P. Algazi, Ammar Sukari, Tanguy Y. Seiwert, Missak Haigentz, Mercedes Porosnicu, Marcelo Bonomi, Jean Boyer, Nicholas M. Durham, Rakesh Kumar, Kevin Laubscher, (unknown), (unknown), (unknown)	16
10	Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy 2017 ·Molecular Therapy ·Nicholas M. Durham, Kathy Mulgrew, Kelly McGlinchey, Noel R. Monks, (unknown), Ronald Herbst, JoAnn Suzich, Scott A. Hammond, Elizabeth J. Kelly	51
11	GITR ligand fusion protein agonist enhances the tumor antigen–specific CD8 T-cell response and leads to long-lasting memory 2017 ·Journal for ImmunoTherapy of Cancer ·Nicholas M. Durham, (unknown), Randall S. MacGill, Kelly McGlinchey, Ching Ching Leow, Scott H. Robbins	31
12	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination 2015 ·Clinical Cancer Research ·Christopher M. Jackson, Christina M. Kochel, Christopher J. Nirschl, Nicholas M. Durham, Jacob Ruzevick, Angela Alme, Brian J. Francica, (unknown), Andrew Daniels, Thomas W. Dubensky, Peter Lauer, Dirk G. Brockstedt, Emily G. Baxi, Peter A. Calabresi, Janis M. Taube, Carlos A. Pardo, Henry Brem, Drew M. Pardoll, Michael Lim, Charles G. Drake	54
13	Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models 2015 ·Neoplasia ·Jonathan Rios‐Doria, Nicholas M. Durham, Leslie Wetzel, Raymond Rothstein, Jon Chesebrough, Nicholas Holoweckyj, Wei Zhao, Ching Ching Leow, Robert E. Hollingsworth	146
14	Abstract 1538: Levels and enzyme activity of CD73 in primary samples from cancer patients 2015 ·Cancer Research ·Qihui Huang, Nicholas M. Durham, Erin Sult, (unknown), Jenny Liu, Nicholas Holoweckyj, Laurie Iciek, Robert E. Hollingsworth, Brett M. Hall, Ronald Herbst, Ching Ching Leow, Kris F. Sachsenmeier	9
15	A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression 2014 ·The Journal of Pathology ·Brian W. Simons, Nicholas M. Durham, Tullia C. Bruno, Joseph F. Grosso, Anthony J. Schaeffer, Ashley E. Ross, Paula J. Hurley, David M. Berman, Charles G. Drake, Praveen Thumbikat, Edward M. Schaeffer	65
16	Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model 2014 ·PLoS ONE ·Zineb Belcaid, Jillian Phallen, Jing Zeng, Alfred P. See, Dimitrios Mathios, (unknown), Sarah E. Nicholas, M. Kellett, Jacob Ruzevick, Christopher M. Jackson, Emilia Albesiano, Nicholas M. Durham, Xiaobu Ye, Phuoc T. Tran, Betty Tyler, John Wong, Henry Brem, Drew M. Pardoll, Charles G. Drake, Michael Lim	181
17	Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo 2014 ·PLoS ONE ·Nicholas M. Durham, Christopher J. Nirschl, Christopher M. Jackson, (unknown), Christina M. Kochel, Robert A. Anders, Charles G. Drake	143
18	Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer 2013 ·Journal of Translational Medicine ·Satoshi Wada, Christopher M. Jackson, Kiyoshi Yoshimura, Hung‐Rong Yen, Derese Getnet, Timothy Harris, Monica V. Goldberg, Tullia C. Bruno, Joseph F. Grosso, Nicholas M. Durham, George J. Netto, Drew M. Pardoll, Charles G. Drake	63
19	Anti‐tumor effects of endogenous prostate cancer‐specific CD8 T cells in a murine TCR transgenic model 2011 ·The Prostate ·Tullia C. Bruno, (unknown), Joseph F. Grosso, Derese Getnet, Hung‐Rong Yen, Nicholas M. Durham, George J. Netto, Drew M. Pardoll, Charles G. Drake	9
20	A role for the transcription factor Helios in human CD4+CD25+ regulatory T cells 2010 ·Molecular Immunology ·Derese Getnet, Joseph F. Grosso, Monica V. Goldberg, Timothy Harris, Hung‐Rong Yen, Tullia C. Bruno, Nicholas M. Durham, Edward L. Hipkiss, (unknown), Satoshi Wada	184

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact